Lexeo Therapeutics Inc. C... (LXEO)
Lexeo Therapeutics Common Stock Statistics
Share Statistics
Lexeo Therapeutics Common Stock has 33.2M shares outstanding. The number of shares has increased by 0.76% in one year.
| Shares Outstanding | 33.2M |
| Shares Change (YoY) | 0.76% |
| Shares Change (QoQ) | 0.4% |
| Owned by Institutions (%) | 87.86% |
| Shares Floating | 25.01M |
| Failed to Deliver (FTD) Shares | 467.8K |
| FTD / Avg. Volume | 59.11% |
Short Selling Information
The latest short interest is 2.94M, so 8.85% of the outstanding shares have been sold short.
| Short Interest | 2.94M |
| Short % of Shares Out | 8.85% |
| Short % of Float | 9.9% |
| Short Ratio (days to cover) | 2.09 |
Valuation Ratios
The PE ratio is -2.13 and the forward PE ratio is -1.33. Lexeo Therapeutics Common Stock's PEG ratio is -0.09.
| PE Ratio | -2.13 |
| Forward PE | -1.33 |
| PS Ratio | 0 |
| Forward PS | 0.4 |
| PB Ratio | 1.79 |
| P/FCF Ratio | -2.56 |
| PEG Ratio | -0.09 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Lexeo Therapeutics Common Stock.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.52, with a Debt / Equity ratio of 0.08.
| Current Ratio | 5.52 |
| Quick Ratio | 5.52 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | -0.1 |
| Debt / FCF | -0.12 |
| Interest Coverage | 772.01 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.37M |
| Employee Count | 72 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -62.04% in the last 52 weeks. The beta is 1.52, so Lexeo Therapeutics Common Stock's price volatility has been higher than the market average.
| Beta | 1.52 |
| 52-Week Price Change | -62.04% |
| 50-Day Moving Average | 3.08 |
| 200-Day Moving Average | 7.2 |
| Relative Strength Index (RSI) | 69.39 |
| Average Volume (20 Days) | 791.34K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -105.77M |
| Net Income | -98.33M |
| EBITDA | -96.22M |
| EBIT | -98.47M |
| Earnings Per Share (EPS) | -3.09 |
Balance Sheet
The company has 35.01M in cash and 9.92M in debt, giving a net cash position of 25.09M.
| Cash & Cash Equivalents | 35.01M |
| Total Debt | 9.92M |
| Net Cash | 25.09M |
| Retained Earnings | -280.17M |
| Total Assets | 146.94M |
| Working Capital | 103.28M |
Cash Flow
In the last 12 months, operating cash flow was -81.15M and capital expenditures -481K, giving a free cash flow of -81.63M.
| Operating Cash Flow | -81.15M |
| Capital Expenditures | -481K |
| Free Cash Flow | -81.63M |
| FCF Per Share | -2.57 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LXEO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for LXEO is $21, which is 344% higher than the current price. The consensus rating is "Buy".
| Price Target | $21 |
| Price Target Difference | 344% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -1.65 |
| Piotroski F-Score | 2 |